Justin Zelin
Stock Analyst at BTIG
(1.89)
# 3,294
Out of 5,008 analysts
42
Total ratings
27.5%
Success rate
-0.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VKTX Viking Therapeutics | Reiterates: Buy | $125 | $31.54 | +296.38% | 5 | Sep 22, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $20 → $7 | $2.43 | +188.07% | 3 | Sep 22, 2025 | |
| SNDX Syndax Pharmaceuticals | Reiterates: Buy | $56 | $16.45 | +240.43% | 3 | Sep 19, 2025 | |
| IMAB I-Mab | Reiterates: Buy | $7 | $4.37 | +60.18% | 2 | Sep 10, 2025 | |
| VSTM Verastem | Reiterates: Buy | $20 | $9.00 | +122.22% | 2 | Sep 9, 2025 | |
| IBRX ImmunityBio | Initiates: Buy | $6 | $2.50 | +140.00% | 1 | Jan 10, 2025 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $42 | $20.13 | +108.64% | 1 | Dec 13, 2024 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | n/a | $0.26 | - | 2 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $55 → $62 | $26.92 | +130.31% | 2 | Jul 9, 2024 | |
| TCRX TScan Therapeutics | Initiates: Buy | $12 | $1.97 | +509.14% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.59 | - | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $1.75 | +45,614.29% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $34.22 | +165.93% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $0.85 | +1,072.20% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.96 | +440.54% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $14.83 | +149.49% | 2 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $31.41 | +186.53% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $9.43 | +228.74% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $59.02 | -73.74% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $10 | $1.86 | +437.63% | 3 | Nov 16, 2022 |
Viking Therapeutics
Sep 22, 2025
Reiterates: Buy
Price Target: $125
Current: $31.54
Upside: +296.38%
Jasper Therapeutics
Sep 22, 2025
Maintains: Buy
Price Target: $20 → $7
Current: $2.43
Upside: +188.07%
Syndax Pharmaceuticals
Sep 19, 2025
Reiterates: Buy
Price Target: $56
Current: $16.45
Upside: +240.43%
I-Mab
Sep 10, 2025
Reiterates: Buy
Price Target: $7
Current: $4.37
Upside: +60.18%
Verastem
Sep 9, 2025
Reiterates: Buy
Price Target: $20
Current: $9.00
Upside: +122.22%
ImmunityBio
Jan 10, 2025
Initiates: Buy
Price Target: $6
Current: $2.50
Upside: +140.00%
Enliven Therapeutics
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $20.13
Upside: +108.64%
Carisma Therapeutics
Dec 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.26
Upside: -
IDEAYA Biosciences
Jul 9, 2024
Maintains: Buy
Price Target: $55 → $62
Current: $26.92
Upside: +130.31%
TScan Therapeutics
May 16, 2024
Initiates: Buy
Price Target: $12
Current: $1.97
Upside: +509.14%
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $7.59
Upside: -
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $1.75
Upside: +45,614.29%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $34.22
Upside: +165.93%
Aug 10, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $0.85
Upside: +1,072.20%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $2.96
Upside: +440.54%
Jul 3, 2023
Maintains: Buy
Price Target: $30 → $37
Current: $14.83
Upside: +149.49%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $31.41
Upside: +186.53%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $9.43
Upside: +228.74%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $59.02
Upside: -73.74%
Nov 16, 2022
Maintains: Buy
Price Target: $21 → $10
Current: $1.86
Upside: +437.63%